サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1261357

胃食道逆流症治療薬の世界市場規模、シェア、産業動向分析レポートタイプ別（制酸剤、プロトンポンプ阻害剤（PPI）、H2受容体遮断剤、プロキネティック剤）、地域別展望・予測、2022年～2028年

Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Regional Outlook and Forecast, 2022 - 2028
出版日: | 発行: KBV Research | ページ情報: 英文 130 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
胃食道逆流症治療薬の世界市場規模、シェア、産業動向分析レポートタイプ別（制酸剤、プロトンポンプ阻害剤（PPI）、H2受容体遮断剤、プロキネティック剤）、地域別展望・予測、2022年～2028年
出版日: 2023年03月31日
発行: KBV Research
ページ情報: 英文 130 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

胃食道逆流症治療薬市場規模は、予測期間中にCAGR2.2％で成長し、2028年には56億米ドルに達すると予想されています。

さらに、酸逆流に悩む人は、持続的な咳、喉頭炎、喘鳴、喉の灼熱感や痛み、喘息の増加、夜間の睡眠障害などを抱えることがあります。まれに、逆流が続くと、狭窄、食道炎、形質転換、悪性腫瘍になることがあります。下部食道括約筋の固有圧力、胸部横隔膜によるLESの外在的圧迫、そしてHisの鋭角が逆流防止バリアを構成していると考えられています。一過性のLES弛緩（TLESR）、LESの低血圧、食道胃接合部（EGJ）の物理的障害、すなわち食道裂孔ヘルニアは、逆流の3大原因とされています。

TLESRは嚥下時に発生し、食道から胃へのボーラスの通過を可能にするもので、健常者やGERD患者のかなりの部分で、逆流の最も重要なメカニズムとなっています。また、二次的な蠕動運動が誘発されますが、この蠕動運動は、主に心下部領域に位置する胃受容体の活性化に始まる迷走神経反射により、食道中部から始まります。その結果、TLESRを引き起こす主な要因は胃の膨張であり、多くの場合、胃の空気や食物の存在によってもたらされます。これは、TLESRがほとんど食後の出来事である理由を説明しています。

COVID-19の影響分析

COVID-19のパンデミック期には、市場にネガティブな影響を与えました。COVID-19が人の健康に及ぼす影響については、パンデミック発生当初から盛んに議論されてきたが、胃食道逆流症（GERD）も例外ではないです。ウイルスがGI（胃腸）管の外に出て、腸-肺軸を介して呼吸器系など他の臓器系に症状を発生させたり、感染や炎症を引き起こすことが懸念されました。体内最大の免疫器官である腸には、繁殖スピードの速いCOVID-19ウイルスのコロニーがあるのかもしれません。このような分析・調査により、COVID-19とGERDの関連性が示されたため、市場の成長は大きく阻害されました。

市場成長の要因

ファストフードの多量摂取による消化器系疾患

ファストフードは、さまざまな有害物質や化学物質、過剰な量の塩分を含んでいるため、当然、膨満感や胃潰瘍、時には胃がんの可能性も高くなります。ファストフードから塩分を多く吸収すると、ナトリウムがより多くの水分を保持するようになり、胃痛や腹部の腫れや膨満感を引き起こす可能性があります。成人におけるファストフードの消費量は、富裕層ほど増加し、年齢とともに減少しました。ファストフードの消費量は男女でほぼ同じで、男性の方が昼食に食べる割合が大きく、女性の方が間食として食べる割合が高いです。ファストフードの消費が世界的に拡大することで、胃食道逆流症の症例が増加し、市場の成長を促進します。

アルコールの消費量の急増

個人的な要因としては、年齢、性別、家庭環境、社会経済的地位などが挙げられます。一つの危険因子が優勢というわけではありませんが、アルコール関連の問題に対してより脆弱な人は、よりアルコールを使用する傾向があります。裕福でない人は、裕福な人に比べて、アルコールの使用による健康上・社会上の問題がより深刻です。また、飲酒は胃食道逆流症のリスクを高めるという研究結果も出ています。アルコールの使用の増加は、この病気の全体的な有病率に影響を与え、胃食道逆流症市場の拡大の原動力となる可能性があります。

市場の抑制要因

胃食道逆流症の薬に伴う副作用の一例

制酸剤は、特定の人にアレルギーを引き起こし、特定の食品にアレルギーを起こしやすくする可能性があります。制酸剤の副作用は、しばしば不適切な服用によって引き起こされます。Maalox、Mylanta、Rolaids、Tumsなど、いくつかの制酸剤にはカルシウムが含まれています。患者さんが推奨される量よりも過剰に、あるいは長く服用した場合、カルシウムの過剰摂取の可能性があります。カルシウムの過剰摂取による症状には、吐き気、嘔吐、精神状態の変化、腎臓結石などがあります。カルシウムの摂りすぎでアルカローシスが起こることもあります。この状態では、体が効果的に働くために十分な酸を生成することができません。患者さんが、気分を良くするために制酸剤をたくさん飲む必要があると感じる場合は、別の病気を示唆している可能性があります。

タイプ別展望

タイプに基づき、胃食道逆流症治療薬市場は、制酸剤、H2受容体遮断剤、プロトンポンプ阻害剤（PPI）、プロキネティック剤に区分されます。2021年の胃食道逆流症治療薬市場では、プロトンポンプ阻害薬（PPI）セグメントが大きな収益シェアを獲得しました。これは、胸焼けや酸欠に関連する症状の治療に最もよく推奨される薬物群であるという事実によるものです。これらの薬剤は、胃の頭頂細胞における酸の産生を抑制することで機能します。PPIは、市販薬と処方薬の両方が提供されています。オメプラゾールとランソプラゾールは、最も長い歴史を持ち、医師や患者さんに最もよく知られた薬です。

地域の展望

地域別に、胃食道逆流症治療薬市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。2021年の胃食道逆流症治療薬市場では、北米地域が最も高い収益シェアを獲得しています。これは、地域住民のGERD発症率の上昇とGERD治療薬の使用率の上昇に起因しています。また、この問題に対する国民の意識を高めるためのキャンペーンも増えており、GERD治療薬の需要を押し上げています。このキャンペーンは、GERDに悩む人々に、逆流を防ぐ簡単なレシピを提供することを目的としています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
    • 世界の胃食道逆流症治療薬市場：タイプ別
    • 世界の胃食道逆流症治療薬市場：地域別
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因

第3章 世界の胃食道逆流症治療薬市場：タイプ別

  • 世界の制酸剤市場：地域別
  • 世界のプロトンポンプ阻害剤（PPI）市場：地域別
  • 世界のH2受容体遮断薬市場：地域別
  • 世界運動促進剤市場：地域別

第4章 世界の胃食道逆流症治療薬市場：地域別

  • 北米
    • 北米の市場：国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場：国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場：国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場：国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第5章 企業プロファイル

  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • GlaxoSmithKline PLC（GSK）
  • Johnson & Johnson
  • Ironwood Pharmaceuticals, Inc
  • Eisai Co, Ltd.
  • Medigus Ltd
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc
  • Camber Pharmaceuticals, Inc（Hetero Labs Limited）
図表

LIST OF TABLES

  • TABLE 1 Global Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 2 Global Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 3 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Global Antacids Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Antacids Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Proton Pump Inhibitors (PPIs) Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Proton Pump Inhibitors (PPIs) Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global H2 Receptor Blockers Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global H2 Receptor Blockers Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Pro-kinetic Agents Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Pro-kinetic Agents Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2022 - 2028, USD Million
  • TABLE 15 North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 16 North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 17 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 18 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 19 North America Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 20 North America Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 21 North America Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 22 North America Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 23 North America H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 24 North America H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 25 North America Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 26 North America Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 27 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 28 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 29 US Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 30 US Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 31 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 32 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 33 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 34 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 35 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 36 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 37 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 38 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 39 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 40 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 41 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 42 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 43 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 44 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 45 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 46 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 47 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 48 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 49 Europe Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 50 Europe Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 51 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 52 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 53 Europe H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 54 Europe H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 55 Europe Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 56 Europe Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 57 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 58 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 59 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 60 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 61 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 62 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 63 UK Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 64 UK Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 65 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 66 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 67 France Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 68 France Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 69 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 70 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 71 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 72 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 73 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 74 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 75 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 76 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 77 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 78 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 79 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 80 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 81 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 82 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 83 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 84 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 85 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 86 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 87 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 88 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 89 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 90 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 91 Asia Pacific Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 92 Asia Pacific Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 93 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Asia Pacific H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Asia Pacific H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Asia Pacific Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Asia Pacific Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 100 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 101 China Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 102 China Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 103 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 104 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 105 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 106 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 107 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 108 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 109 India Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 110 India Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 111 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 112 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 113 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 114 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 115 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 116 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 117 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 118 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 119 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 120 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 121 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 122 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 123 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 124 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 125 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 126 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 127 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 128 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 129 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 130 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 131 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 132 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 133 LAMEA Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 134 LAMEA Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 135 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 136 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 137 LAMEA H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 138 LAMEA H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 139 LAMEA Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 140 LAMEA Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 141 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 142 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 143 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 144 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 145 2023
  • TABLE 146 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 147 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 148 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 149 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 150 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 151 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 152 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 153 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 154 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 155 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 156 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 157 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 158 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 159 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 160 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 161 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 162 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 163 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 164 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 165 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 166 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 167 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 168 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 169 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 170 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 171 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 172 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 173 KEY INFORMATION - AstraZeneca PLC
  • TABLE 174 Key Information - GlaxoSmithKline PLC
  • TABLE 175 Key information -Johnson & Johnson
  • TABLE 176 Key Information - Ironwood Pharmaceuticals, Inc.
  • TABLE 177 Key Information - Eisai Co., Ltd.
  • TABLE 178 Key Information - Medigus Ltd.
  • TABLE 179 Key Information - Sebela Pharmaceuticals
  • TABLE 180 Key Information - Phathom Pharmaceuticals, Inc.
  • TABLE 181 Key Information - Camber Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2021
  • FIG 3 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2028
  • FIG 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2028, USD Million
  • FIG 5 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2021
  • FIG 6 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2028
  • FIG 7 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2028, USD Million
目次

The Global Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 2.2% CAGR during the forecast period.

A digestive illness called gastroesophageal reflux disease (GERD) occurs when stomach contents, including acid, food, and liquids, leak into the esophagus. The lining of the esophagus is irritated, giving patients a burning feeling. Heartburn (reflux) and regurgitation are the primary esophageal symptoms defining GERD. Moreover, GERD may result in esophageal inflammation if ignored for a long time. It is linked to sleep problems and low quality of life.

Upper endoscopy, an ambulatory acid (PH) probe test, esophageal manometry, and X-rays are the primary methods used to diagnose it. Changing one's lifestyle and using regulated drugs might help manage certain conditions, but others may also need surgery or powerful medications. Burning in the chest, dysphagia, belching, epigastric discomfort, trouble swallowing, regurgitation of food or sour liquid, and a lump in the throat are typical indications and symptoms of the condition.

Moreover, acid reflux sufferers may have a persistent cough, laryngitis, wheezing, burning or painful throat sensations, increasing asthma, and sleep difficulties at night. In rare cases, persistent reflux may result in stricture, esophagitis, metaplasia, or malignancy. The lower esophageal sphincter's intrinsic pressure, the crural diaphragm's extrinsic compression of the LES, and the acute angle of His are hypothesized to make up the anti-reflux barrier. Transient LES relaxations (TLESRs), LES hypotension, and physical disruption of the esophagogastric junction (EGJ), or hiatus hernia, are the three most common causes of reflux.

TLESRs, which occur during swallows to allow the passage of a bolus from the esophagus into the stomach, are the most important mechanism of reflux in healthy subjects and a significant portion of GERD patients. They are also induced by secondary peristalsis, which starts from the mid-esophagus due to a vago-vagal reflex beginning with the activation of gastric receptors primarily located in the sub-cardiac region. As a result, the primary factor that causes a TLESR is stomach distension, often brought on by gastric air or the presence of food, which explains why TLESRs are mostly a postprandial event.

COVID-19 Impact Analysis

The COVID-19 pandemic affected the market negatively during the pandemic phase. COVID-19's effects on many aspects of human health have been extensively discussed since the start of the pandemic, and gastroesophageal reflux disease (GERD) is no exception. There was a worry that the virus may move beyond the GI (gastrointestinal) tract by generating symptoms in other organ systems, such as the respiratory system, through a gut-lung axis or by causing infection or inflammation. The gut, the body's biggest immunological organ, may be home to colonies of COVID-19 virus, which reproduces quickly. Because of the association between COVID-19 and GERD shown by such analysis and research, the market growth was hampered significantly.

Market Growth Factors

High intake of fast food causing digestive diseases

Fast food naturally raises the chance of bloating, stomach ulcers, and sometimes even stomach cancer since it includes a variety of hazardous substances, chemicals, and excessive amounts of salt. If the body absorbs more salt (from fast food), the sodium will retain more water, which may cause stomach pain and abdominal swelling or bloating. Fast food consumption among adults rose with wealth while decreasing with age. Fast food consumption was similar across men and women, with a more significant proportion of men eating it for lunch and a higher proportion of women eating it as a snack. The growing consumption of fast food globally will increase the cases of gastroesophageal reflux diseases and propel market growth.

The surging consumption of alcohol

Personal factors include age, gender, domestic circumstances, and socioeconomic status. Although no one risk factor predominates, those who are more vulnerable to alcohol-related problems are more likely to use alcohol. Less wealthy individuals have more significant health and social issues due to alcohol use than more affluent individuals. Studies have also shown that drinking alcohol increases the risk of gastroesophageal reflux disease. The growing use of alcohol will have an impact on the disease's overall prevalence and may help drive the gastroesophageal reflux diseases market expansion.

Market Restraining Factors

Some side effects associated with gastroesophageal reflux disease's medications

Antacids may cause allergies in certain persons and make it more likely for people to become allergic to certain foods. Antacid side effects are often caused by improper dosage. Several antacids include calcium, including Maalox, Mylanta, Rolaids, and Tums. A calcium overdose is possible if the patient takes them in excess or longer than recommended. Symptoms of too much calcium include nausea, vomiting, altered mental state, and kidney stones. Alkalosis may also result from too much calcium. The body can't produce enough acid in this state for it to work effectively. It might indicate another disease if the patient feels they need to take a lot of antacids to feel better.

Type Outlook

Based on type, the gastroesophageal reflux disease therapeutics market is segmented into antacids, H2 receptor blockers, proton pump inhibitors (PPIs) and pro-kinetic agents. The proton pump inhibitors (PPIs) segment acquired a significant revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is due to the fact that it is the most often recommended family of medications for treating heartburn and conditions linked to acidity. They work by inhibiting acid production in the stomach's parietal cells. Both over-the-counter and prescription PPIs are offered. Omeprazole and lansoprazole are two medications that have been around the longest and are thus the most well-known to doctors and patients.

Regional Outlook

Region-wise, the gastroesophageal reflux disease therapeutics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is owing to the increased incidence of GERD in the local population and the rising use of GERD therapies. Also, there are more and more campaigns to raise public awareness of the problem, driving up demand for GERD treatments. The campaign aimed to provide GERD sufferers with simple-to-follow recipes that are reflux-friendly.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

Market Segments covered in the Report:

By Type

  • Antacids
  • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Blockers
  • Pro-kinetic Agents

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigus Ltd.
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market, by Type
    • 1.4.2 Global Gastroesophageal Reflux Disease Therapeutics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition & scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market by Type

  • 3.1 Global Antacids Market by Region
  • 3.2 Global Proton Pump Inhibitors (PPIs) Market by Region
  • 3.3 Global H2 Receptor Blockers Market by Region
  • 3.4 Global Pro-kinetic Agents Market by Region

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market by Region

  • 4.1 North America Gastroesophageal Reflux Disease Therapeutics Market
    • 4.1.1 North America Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.1.1 North America Antacids Market by Country
      • 4.1.1.2 North America Proton Pump Inhibitors (PPIs) Market by Country
      • 4.1.1.3 North America H2 Receptor Blockers Market by Country
      • 4.1.1.4 North America Pro-kinetic Agents Market by Country
    • 4.1.2 North America Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.1.2.1 US Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.1.1 US Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.2 Canada Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.2.1 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.3 Mexico Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.4 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.4.1 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.2 Europe Gastroesophageal Reflux Disease Therapeutics Market
    • 4.2.1 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.1.1 Europe Antacids Market by Country
      • 4.2.1.2 Europe Proton Pump Inhibitors (PPIs) Market by Country
      • 4.2.1.3 Europe H2 Receptor Blockers Market by Country
      • 4.2.1.4 Europe Pro-kinetic Agents Market by Country
    • 4.2.2 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.2.2.1 Germany Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.1.1 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.2 UK Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.3 France Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.3.1 France Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.4 Russia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.4.1 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.5 Spain Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.5.1 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.6 Italy Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.7 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.7.1 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
    • 4.3.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.1.1 Asia Pacific Antacids Market by Country
      • 4.3.1.2 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country
      • 4.3.1.3 Asia Pacific H2 Receptor Blockers Market by Country
      • 4.3.1.4 Asia Pacific Pro-kinetic Agents Market by Country
    • 4.3.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.3.2.1 China Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.1.1 China Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.2 Japan Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.3 India Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.3.1 India Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.4 South Korea Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.4.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.5 Singapore Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.5.1 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.6 Malaysia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.6.1 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.7 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.7.1 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.4 LAMEA Gastroesophageal Reflux Disease Therapeutics Market
    • 4.4.1 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.1.1 LAMEA Antacids Market by Country
      • 4.4.1.2 LAMEA Proton Pump Inhibitors (PPIs) Market by Country
      • 4.4.1.3 LAMEA H2 Receptor Blockers Market by Country
      • 4.4.1.4 LAMEA Pro-kinetic Agents Market by Country
    • 4.4.2 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.4.2.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.1.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.2 Argentina Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.2.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.3 UAE Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.3.1 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.4 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.4.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.5 South Africa Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.5.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.6 Nigeria Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.6.1 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.7 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.7.1 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type

Chapter 5. Company Profiles

  • 5.1 Takeda Pharmaceutical Company Limited
    • 5.1.1 Company Overview
    • 5.1.2 Financial Analysis
    • 5.1.3 Regional Analysis
    • 5.1.4 Research & Development Expense
  • 5.2 AstraZeneca PLC
    • 5.2.1 Company Overview
    • 5.2.2 Financial Analysis
    • 5.2.3 Regional Analysis
    • 5.2.4 Research & Development Expenses
  • 5.3 GlaxoSmithKline PLC (GSK)
    • 5.3.1 Company Overview
    • 5.3.2 Financial Analysis
    • 5.3.3 Segmental and Regional Analysis
    • 5.3.4 Research & Development Expense
  • 5.4 Johnson & Johnson
    • 5.4.1 Company Overview
    • 5.4.2 Financial Analysis
    • 5.4.3 Segmental &Regional Analysis
    • 5.4.4 Research & Development Expenses
  • 5.5 Ironwood Pharmaceuticals, Inc.
    • 5.5.1 Company Overview
    • 5.5.2 Financial Analysis
    • 5.5.3 Regional Analysis
    • 5.5.4 Research & Development Expenses
  • 5.6 Eisai Co., Ltd.
    • 5.6.1 Company Overview
    • 5.6.2 Financial Analysis
    • 5.6.3 Segmental and Regional Analysis
    • 5.6.4 Research & Development Expenses
  • 5.7 Medigus Ltd.
    • 5.7.1 Company Overview
    • 5.7.2 Financial Analysis
    • 5.7.3 Segmental and Regional Analysis
    • 5.7.4 Research & Development Expenses
  • 5.8 Sebela Pharmaceuticals
    • 5.8.1 Company Overview
    • 5.8.2 Recent strategies and developments:
      • 5.8.2.1 Partnerships, Collaborations, and Agreements:
  • 5.9 Phathom Pharmaceuticals, Inc.
    • 5.9.1 Company Overview
    • 5.9.2 Research & Development Expenses
    • 5.9.3 Recent strategies and developments:
      • 5.9.3.1 Partnerships, Collaborations, and Agreements:
  • 5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
    • 5.10.1 Company Overview
    • 5.10.2 Recent strategies and developments:
      • 5.10.2.1 Product Launches and Product Expansions: